Atara Biotherapeutics Stock (NASDAQ:ATRA)
Previous Close
$10.61
52W Range
$6.50 - $39.50
50D Avg
$9.23
200D Avg
$12.44
Market Cap
$66.06M
Avg Vol (3M)
$148.73K
Beta
0.49
Div Yield
-
ATRA Company Profile
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
ATRA Performance
Peer Comparison
Ticker | Company |
---|---|
SANA | Sana Biotechnology, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
BTAI | BioXcel Therapeutics, Inc. |
VECT | VectivBio Holding AG |
MREO | Mereo BioPharma Group plc |
FATE | Fate Therapeutics, Inc. |
APLS | Apellis Pharmaceuticals, Inc. |
TCRX | TScan Therapeutics, Inc. |
RCUS | Arcus Biosciences, Inc. |
HOOK | HOOKIPA Pharma Inc. |
HRTX | Heron Therapeutics, Inc. |
KPTI | Karyopharm Therapeutics Inc. |
CRBU | Caribou Biosciences, Inc. |
ALLO | Allogene Therapeutics, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
ITOS | iTeos Therapeutics, Inc. |